

## Epysqli<sup>®</sup> (eculizumab-aagh) – First-time biosimilar launch

- On April 7, 2025, [Teva](#) and [Samsung Bioepis announced](#) the launch of [Epysqli \(eculizumab-aagh\)](#), biosimilar to AstraZeneca's [Soliris \(eculizumab\)](#).
  - Epysqli is available at a list price (Wholesale Acquisition Cost [WAC]) 30% below the current Soliris intravenous 300 mg/30 mL list price (\$6,523.00 per package).
- The [FDA approved](#) Epysqli in July 2024.
- Epysqli and Soliris share the following indications:
  - The treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis
  - The treatment of patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy.
- Soliris is also approved for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive and neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

